Real-world impact of dupilumab on asthma disease burden in Japan: The CROSSROAD study

Background: Dupilumab, a human monoclonal anti-interleukin (IL)-4Ra antibody blocks the shared receptor component of IL-4 and IL-13, drivers of type 2 inflammation. Dupilumab is approved for severe/refractory asthma inadequately controlled by existing therapies, but knowledge of its effect on real-w...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Koichi Fukunaga, Etsuko Tagaya, Masato Ishida, Yoshinori Sunaga, Ryuji Koshiba, Akihito Yokoyama
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2023-10-01
סדרה:	Allergology International
נושאים:	Adrenal cortex hormones Asthma Disease progression Dupilumab Retrospective study
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S1323893023000394
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!